Billings Clinic
Especially For:

Clinical Trials

Title   Melanoma E2607
Description   CTSU E2607  A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas
IRB Number   E2607
Category   Melanoma
Inclusion/Notes   No previous treatment with any targeted therapies. Must have measurable disease, If RT has been administered to a lesion, there must be radiographic evidence of progression of that lesion in order for that lesion to constitute measurable disease or to be included in the measured target lesions.
Status   Active
Start Date   05/21/2012
Principal Investigator (PI)   Brock Whittenberger, MD
Contact Name   Judy Miller RN
Contact Email   jmiller4@billingsclinic.org
Phone   (406) 435-7482
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.